Financials in USD. Standardized financial statements.
A compact view of how Kiniksa Pharmaceuticals, Ltd. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $677.56M | $423.24M | $270.26M | $220.18M | $38.54M | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +60.1% | +56.6% | +22.7% | +471.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $307.41M | $60.91M | $56.52M | $22.89M | $9.10M | $3.81M | $3.28M | $286,000 | $28,000 | $22,000 |
| Gross Profit? | $370.15M | $362.33M | $213.74M | $197.28M | $29.44M | -$3.81M | -$3.28M | -$286,000 | -$28,000 | -$22,000 |
| Gross Margin? | +54.6% | +85.6% | +79.1% | +89.6% | +76.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $292.93M | $407.94M | $238.93M | $187.51M | $186.08M | $153.56M | $166.68M | $108.16M | $65.40M | $24.00M |
| Operating Income? | $77.22M | -$45.62M | -$25.20M | $9.77M | -$156.64M | -$157.36M | -$169.96M | -$108.16M | -$65.40M | -$24.00M |
| EBITDA? | $90.42M | -$43.92M | -$22.86M | $12.18M | -$154.28M | -$152.42M | -$160.63M | -$107.87M | -$65.37M | -$23.98M |
| Income Before Tax | $88.87M | -$36.15M | -$16.65M | $11.03M | -$156.54M | -$156.23M | -$163.91M | -$103.44M | -$64.87M | -$23.94M |
| Income Tax Expense | $29.86M | $7.04M | -$30.74M | -$172.34M | $1.39M | $5.15M | -$2.05M | -$214,000 | $2,000 | $36,000 |
| Net Income? | $59.01M | -$43.19M | $14.08M | $183.36M | -$157.92M | -$161.38M | -$161.87M | -$103.23M | -$64.87M | -$23.97M |
| EPS? | $0.80 | $-0.60 | $0.20 | $2.64 | $-2.30 | $-2.61 | $-2.99 | $-3.49 | $-2.00 | $-0.74 |
| Diluted EPS? | $0.75 | $-0.60 | $0.20 | $2.60 | $-2.30 | $-2.61 | $-2.99 | $-3.49 | $-2.00 | $-0.74 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality